Nivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.